Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report published on Monday, Benzinga reports. The brokerage currently has a $32.00 price objective on the stock.

KURA has been the subject of several other reports. JMP Securities reissued a market outperform rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, June 18th. Wedbush reissued an outperform rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, May 3rd. Finally, StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $28.36.

Kura Oncology Stock Up 0.7 %

KURA stock opened at $21.08 on Monday. The company has a market cap of $1.61 billion, a P/E ratio of -9.71 and a beta of 0.94. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The stock’s 50 day simple moving average is $20.61 and its 200 day simple moving average is $19.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) earnings per share. On average, research analysts expect that Kura Oncology will post -2.56 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the company. Artal Group S.A. grew its holdings in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after purchasing an additional 151,828 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares during the period. Avoro Capital Advisors LLC grew its holdings in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the period. Affinity Asset Advisors LLC grew its holdings in Kura Oncology by 281.4% during the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares during the period. Finally, Platinum Investment Management Ltd. bought a new position in Kura Oncology during the first quarter valued at $998,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.